Carcinoma In Situ Clinical Trials in Houston, Texas

8 recruitingHouston, Texas

Showing 18 of 8 trials

Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled75 locationsNCT06545955
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Invasive Breast CarcinomaBreast Ductal Carcinoma in SituHereditary Breast Carcinoma+1 more
M.D. Anderson Cancer Center600 enrolled4 locationsNCT04169542
Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting

The PREDICT Registry:

DCISDuctal Breast Carcinoma In SituStage 0 Breast Cancer
PreludeDx3,000 enrolled30 locationsNCT03448926
Recruiting
Not Applicable

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+20 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT02918474
Recruiting
Phase 1

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Triple-Negative Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Cancer+11 more
OncoNano Medicine, Inc.168 enrolled16 locationsNCT06022029